Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin

Česká verzia

Authors: M. Tajtáková ¹; Z. Semanová ¹; G. Ivančová ²; J. Petrovičová ³; V. Doničová ²; E. Žemberová ⁴
Authors place of work: I. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednosta prof. MUDr. Ivica Lazúrová, CSc. ¹; Interná a diabetologická ambulancia NZZ, Košice, Slovenská republika ²; Ústav lekárskej informatiky Lekárskej fakulty UPJŠ Košice, Slovenská republika, prednosta Ing. Jaroslav Majerník, Ph. D. ³; RIA laboratórium Košice, Slovenská republika, vedúca PharmDr. Eva Žemberová ⁴
Published in the journal: Vnitř Lék 2007; 53(9): 960-963
Category: Original Contributions

Summary

Objective:
Is there a difference between the retinol-binding protein 4 (RBP4) levels in obese patients with insulin resistance (IR) without diabetes, in obese patients with type 2 diabetes mellitus (DM2T) treated with metformin and in nonobese healthy individuals?

Method:
28 obese individuals with insulin resistance, 11 type 2 diabetes patients treated with metformin and 17 control individuals were examined for serum level of retinol-binding protein 4 using the RIA method. The results were compared within the groups and RBP4 was correlated with insulin in the IR group and the control group.

Outcome:
The highest and the lowest RBP4 levels (561.6 ± ± 209 ng/ml) were recorded, respectively, for obese individuals with IR (IR HOMA 3.9) and for obese type 2 diabetics treated with metformin (391.1 ± 133,5 ng/ml) (P < 0.01). The RBP4 level of the control group was significantly lower as compared with the obese individuals with IR (452.8 ± 104.6 ng/ml) (P < 0.05), but insignificantly higher as compared with the obese individuals with DM2T treated with metformin (391.1 ± 133.5 ng/ml). RBP4 in the monitored group correlated with insulin r = 0.46 (p < 0.03).

Conclusion:
The increase in RBP4 in obese individuals by GLUT4 regulation in adipocytes contributes to the development and aggravation of systemic IR. Through its effect on RBP4 expression in adipocytes, metformin may improve total insulin sensitivity in obese individuals including those with MS and delay the onset of manifest DM. RBP4 could by used as a marker of deteriorating glucose tolerance in obese individuals.

Key words:
obesity – type 2 diabetes mellitus – metformin – retinol-binding protein 4

Zdroje

1. Anderwald C, Roden M. Adipotoxicity and the insulin resistance syndrome. Pediatr Endocrinol Rev 2004; 1: 310-319.

2. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 2002; 3: 267-277.

3. Carvalho E, Kotani K, Peroni OD et al. Adipose- specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle. Am J Physiol Endocrinol Metab 2005; 289: E551-E561.

4. Craig RL, Chu WS, Elbein SC. Retinol binding protein 4 as a candidate gene for type 2 diabetes and prediabetic intermediate traits. Mol Genet Metab 2006; PMID: 17174134.

5. Dorosa G, D´Angelo A, Ragonesi PD et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006; 31: 375-383.

6. Eldor R, Raz I. Lipotoxicity versus adipotoxicity - The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes. Diabetes Res Clin Pract 2006; PMID: 16891032.

7. Gonzalez E, McGraw TE. Insulin signaling diverges into act dependent and independent signals to regulate the recruitment/docking and the fusion of GLUT4 vesicles to the plasma membrane. Mol Biol Cell 2006; PMID: 16914513.

8. Graham TE, Yang Q, Bluher M et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-2563.

9. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004; 30: 13-19.

10. Heilbronn L, Smith ER, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord 2004; 28: S4: 12-21.

11. Cho YM, Youn BS, Lee H et al. Plasma retinol-binding protein 4 concentrations are eleved in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006; 29: 2457- 2461.

12. Janke J, Engeli S, Boschmann M et al. Retinol-binding protein 4 in human obesity. Diabetes 2006; 55: 2805-2810.

13. Kanai M, Raz A, Goodman S. Retinol binding protein: the transport protein for vitamin A in human plasma. J Clin Invest 1968; 47: 2025-2044.

14. Kotani K, Peroni OD, Minokoshi Y et al. GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization. J Clin Invest 2004; 114: 1666-1675.

15. Kubota N, Terauchi Y, Kubota T et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 2006; 281: 8748-8755.

16. Moon RJ, Bascombe LA, Holt RI. The addition of metformin in type l diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes Obes Metab 2007; 9: 143-145.

17. Noy N. Retinoid-binding proteins: mediators of retinoid action. Biochem J 2000; 348: 481-495.

18. Osei K, Gaillard T, Schuster D. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerence and type 2 diabetes mellitus. A pilot study of rosiglitazone. Metabolism 2007; 56: 24-29.

19. Polonsky KS. Retinol-binding protein 4, insulin resistance and type 2 diabetes. N Engl J Med 2006; 354: 2596-2598.

20. Radíková Z. Assessment of insulin sensitivity/resistance in epidemiological studies. Endocrine Regulations 2003; 37: 188-194.

21. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an uptade. Clin Endocrinol (Oxf) 2006; 64: 355-365.

22. Steals B. Metformin and pioglitazone: Effectively treating insulin resistance. Curr Med Res Opin 2006; 22(Suppl 2): S27-S37.

23. Sharma PK, Bhansali A, Sialy R et al. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2006; 65: 722-728.

24. Tajtáková M, Petrášova D, Petrovičova J et al. Adiponectin as a biomarker of clinical manifestation of metabolic syndrome. Endocrine Regulations 2006; 40: 1-6.

25. Yang Q, Graham TE, Mody N et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-362.

26. Zorzano A, Palaci M, Gumá A. Mechanisms regulating GLUT4 glucose transporter expression and glucose transport in skeletal muscle. Acta Physiologica 2005; 183: 43-58.